Corvus Pharmaceuticals, Inc. — Director's Dealing 2025

Dec 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2025-12-04

Reporting Person: Jones William Benton (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-04	Stock Option (Right to Buy)	$8.81	A	400000	Acquired	2035-12-04	Common Stock (400000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.